deltatrials
Completed PHASE3 NCT00241527

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo and Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs

Sponsor: AstraZeneca

Conditions NSAIDs Upper GI Symptoms
Interventions Esomeprazole
Updated 6 times since 2017 Last updated: Jan 21, 2011 Started: Dec 31, 2000 Primary completion: Sep 30, 2002 Completion: Sep 30, 2002

This PHASE3 trial investigates NSAIDs and Upper GI Symptoms and is currently completed. AstraZeneca leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ashford, United Kingdom, Audley, United Kingdom, Bari, Italy, Bath, United Kingdom, Bergen, Norway, Bloemfontein, South Africa, Bodø, Norway, Bradenton, United States, Bradford Upon Avon, United Kingdom, Bratislava, Slovakia and 116 more location s